Abstract
Inflammatory myofibroblastic tumor (IMT), previously known as inflammatory pseudotumor, is a rare lesion of unclear etiology characterized by myofibroblastic spindle cells and inflammatory infiltrates. This case report describes a 74-year-old female with a recurrent 10-cm retroperitoneal IMT that appeared 30 months after initial surgery. The tumor involved the descending colon and caused left hydroureteronephrosis. Successful en bloc re-resection, including a partial colectomy, was achieved. At a 24-month follow-up, the patient remained disease-free, reinforcing that complete surgical extirpation is the gold standard for both primary and recurrent IMT lesions.
The Challenge of Retroperitoneal IMT
Inflammatory myofibroblastic tumors occupy a complex middle ground in oncology, possessing "intermediate biological potential." While they are not classically malignant, they are not entirely benign either. When located in the retroperitoneum—the space behind the abdominal cavity—these tumors tend to be more aggressive and difficult to treat than their pulmonary counterparts.
The primary clinical challenge is their unpredictability and high propensity for local recurrence (up to 25%). Because they often present with non-specific symptoms like fever and weight loss, they are frequently misidentified as infections or other malignancies until a biopsy is performed.
Diagnostic Imaging and Surgical Intervention
In this case, contrast-enhanced Computed Tomography (CT) was used to identify the mass and evaluate its relationship to surrounding organs. The imaging revealed a large paravertebral mass necessitating aggressive intervention.
To manage the recurrence, surgeons performed an en bloc resection, removing the tumor as a single piece along with adherent tissue (a partial colectomy) to ensure clear margins. Histopathology and immunohistochemistry (IHC) confirmed the diagnosis, showing positive markers for vimentin, CD68, and desmin, which are characteristic of myofibroblastic origin.
Comparative Analysis and Literature Review
Because retroperitoneal IMT is exceptionally rare—with only 12 cases reported in English literature at the time of this study—there is no standardized protocol for managing recurrences. The authors provided a meta-summary table to track patient demographics, tumor size, treatment methods, and outcomes across these known cases.
The literature review highlights the variable "biological potential" of these tumors, with outcomes ranging from long-term disease-free survival to rapid progression. The study reinforces that complete surgical removal is the only reliable treatment to prevent further recurrence.
Key Insights and Future Directions
- Surgical Primacy: Aggressive en bloc resection remains the primary treatment. If the tumor adheres to adjacent organs, partial resection of those organs is necessary to ensure no tumor cells remain.
- The ALK Connection: Approximately 50% of IMTs involve chromosomal rearrangements of the ALK gene. While not the focus of this specific case, ALK inhibitors like crizotinib represent a promising systemic therapy for future cases where surgery is not feasible.
- Long-term Monitoring: Given the tumor's history of late recurrence, vigilant long-term monitoring is essential. The 24-month disease-free status in this patient is encouraging, but further follow-up is required to confirm a permanent cure.
In conclusion, this case demonstrates that even large, recurrent retroperitoneal IMTs can be successfully managed through aggressive secondary surgical intervention, providing a blueprint for treating this rare and elusive neoplasm.
Summary updated